Alternatives to RBC Transfusion: Erythropoietin and beyond
|
|
- Shanon Carroll
- 6 years ago
- Views:
Transcription
1 Alternatives to RBC Transfusion: Erythropoietin and beyond David Shimabukuro, MDCM Department of Anesthesia and Perioperative Care Medical Director, 13 ICU UC SF 1
2 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 2
3 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 3
4 Basic Physiology global oxygen delivery = global blood flow x arterial oxygen content DO 2 = CO x CaO 2 CO = SV x HR CaO 2 = ([Hgb] x SaO 2 x Hgb O 2 -binding capacity) + (PaO 2 x plasma O 2 solubility) CaO 2 = 1.39 ([Hgb]) (SaO 2 ) (PaO 2 ) UC SF 4
5 Physiology of Anemia DO 2 = CO x (%Sat x 1.39 x [Hgb]) To maintain oxygen delivery in euvolemia with a decrease in [Hgb] Increase in CO Right shift of hgb-oxygen saturation curve for optimal loading/unloading of oxygen UC SF 5
6 Physiology of Anemia Increase in CO Decrease in viscosity Increase in sympathetic tone UC SF 6
7 Physiology of Anemia Decrease in viscosity Increase in preload Non-Newtonian Fluid Viscosity is highest in post-capillary venules where flow is lowest Disproportionate decrease in blood viscosity, significant increase in venous return Decrease in afterload UC SF 7
8 Physiology of Anemia Increase in sympathetic tone Increase in heart rate Increase in contractility Mediated via stimulation of aortic chemoreceptors UC SF 8
9 UC SF 9
10 Physiology of Anemia For the most part, there is reserve in the system Oxygen extraction is about 20-30% at rest Tolerate rather low hemoglobin levels without sequelae UC SF 10
11 Physiology of Anemia At some point a critical point is reached DO 2 = CO x {(%Sat x 1.39 x [Hgb])} + (.003 x PaO2)} UC SF 11
12 DO2crit Delivery dependent VO2 Delivery independent VO2 VO2 SvO2 OER Lactate NADH Red CtOx DO2 DO2 UC SF 12
13 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 13
14 Controversies Infection RISKS BENEFITS UC SF 14
15 Controversies Infection RISKS BENEFITS UC SF 15
16 Controversies Infection RISKS BENEFITS UC SF 16
17 Guidelines Crit Care Med 2009 Vol. 37, No. 12 UC SF 17
18 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 18
19 Conservation Decrease laboratory testing Remove invasive lines Decrease waste amount/return to patient Minimize amount drawn UC SF 19
20 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 20
21 Erythropoietin Stimulates bone marrow to produce red blood cells Elevated in anemia Blunted levels in critically ill Interleukin-1 Tumor necrosis factor Anemia of critical illness UC SF 21
22 Erythropoietin Corwin and colleagues Prospective, randomized, double-blind, placebo-controlled, multicenter trial Assess weekly dosing of recombinant human erythropoietin (rhuepo) of 40,000 units to decrease occurrence of RBC transfusion (transfusion independence) Corwin, et al. JAMA 288;22: UC SF 22
23 Erythropoietin 1302 patients 650 rhuepo and 652 placebo Received SQ injection on ICU day 3 Study days 1, 7, and 14 Held if HCT > 37% Exclusion Renal Failure on dialysis Acute ischemic heart disease Acute GI bleeding UC SF 23
24 Erythropoietin Transfusion protocol No RBC transfusion if Hgb > 90 g/l, unless clinically indicated For Hgb < 90 g/l, transfusion at the discretion of the physician UC SF 24
25 Erythropoietin Baseline Hemoglobin (g/dl) Total number placebo Total number rhuepo < Mean pretransfusion Hgb 8.5 g/dl UC SF 25
26 Erythropoietin Placebo rhuepo Total number of units transfused Units transfused per patient: Mean Units transfused per patient: Median UC SF 26
27 Erythropoietin Conclusion Weekly administration of rhuepo reduces allogeneic RBC transfusion and increases hemoglobin Addresses only RBC transfusion and not powered for mortality or significant adverse events Transfusion decided by individual physicians UC SF 27
28 Erythropoietin Corwin and colleagues (NEJM Sept 6 07) Efficacy and Safety of Epoetin Alfa in Critically Ill Patients Multicenter, prospective, randomized, placebo-controlled trial ( ) UC SF 28
29 Erythropoietin Primary Endpoint: percentage of patients receiving RBC transfusion between study days 1 and 29 Secondary Endpoints: number of RBC units transfused between days 1 and 42, mortality at day 29 and 140 UC SF 29
30 Erythropoietin Inclusion Criteria Age > 18 Hgb < 12 g/dl At least 2 days in ICU Exclusion Critieria Acute ischemic heart disease during ICU stay History of DVT, PE, or ischemic stroke Dialysis Uncontrolled hypertension UC SF 30
31 Erythropoietin UC SF 31
32 Erythropoietin Epoetin Alfa 40,000 units or placebo was given SQ on study day 1 and weekly for a total of 3 doses (days 1, 8, and 15) Study drug withheld from patients with Hgb > 12 g/dl (for second and third doses) All patients received PO iron on day 1 or when able to take PO UC SF 32
33 Erythropoietin RBC transfusion determined by physician Target Hgb: 7-9 g/dl Transfusion not recommended if Hgb > 9 g/dl or Hct > 27 unless specific clinical indication (active bleeding or ischemia) No Hgb level of Hct concentration for which transfusion was mandated UC SF 33
34 Erythropoietin Baseline characteristics same between study drug and placebo groups However Surgical patients and medical patients were older than trauma patients (mean 64 vs 60 vs 41) Surgical patients and medical patients had more one or more coexisiting diseases (89% vs 89% vs 32%) UC SF 34
35 Erythropoietin UC SF 35
36 Erythropoietin UC SF 36
37 Erythropoietin UC SF 37
38 Erythropoietin UC SF 38
39 Erythropoietin Conclusions: No difference in percentage of patients receiving RBC transfusions between the Epoetin Alfa and placebo groups Decrease in 29-day and 140-day mortality for trauma patients who receive Epoetin Alfa versus placebo and may be beneficial Non-trauma surgical and medical patients should not receive Epoetin Alfa, unless there is an approved indication UC SF 39
40 Erythropoietin However Significant increase in thrombotic complications in the Epoetin Alfa group over the placebo group UC SF 40
41 Erythropoietin Crit Care Med 2009 Vol. 37, No. 12 UC SF 41
42 Erythropoietin Crit Care Med 2009 Vol. 37, No. 12 UC SF 42
43 Agenda Physiology of Oxygen Transport and Anemia Just a few words Controversies of RBC transfusion Risks versus the benefits Solutions/Alternatives to RBC transfusion Conservation Erythropoietin Artificial oxygen carriers UC SF 43
44 Hemoglobin-based Oxygen Carriers UC SF 44
45 Hemoglobin-based Oxygen Carriers Oxyhemoglobin Saturation (%) RBC Hemoglobin Hemoglobin-based Oxygen Carrier Stroma Free Hemoglobin PaO2 (mmhg) UC SF 45
46 Hemoglobin-based Oxygen Carriers Cross-linked Hb (intramolecular) Polymerized Hb (intermolecular) Conjugated Hb UC SF 46
47 Hemoglobin-based Oxygen Carriers Cross-linked Hb Napolitano Crit Care Clin 25 (2009) UC SF 47
48 Hemoglobin-based Oxygen Carriers Polymerized Hb Napolitano Crit Care Clin 25 (2009) UC SF 48
49 Hemoglobin-based Oxygen Carriers Conjugated Hb Napolitano Crit Care Clin 25 (2009) UC SF 49
50 Hemoglobin-based Oxygen Carriers Renal Failure Precipitation in tubules Systemic and Pulmonary Hypertension NO scavenging UC SF 50
51 Hemoglobin-based Oxygen Carriers Resolution of initial problems with second and third generation HBOC Some still with issues, others in phase II and phase III clinical trials UC SF 51
52 Hemoglobin-based Oxygen Carriers Class Product Company Technology Status Cross-linked HemAssist (DCL) Baxter Cross-linked Discontinued US Army Cross-linked Discontinued rhb 1.1 Somatogen rhb Discontinued rhb 2.0 Baxter rhb Discontinued Polymerized PolyHeme Northfield Laboratories Gluteraldehyde, pyridoxal Hb HemoPure Biopure Glutaraldehyde bovine Hb Phase III Phase III HemoLink Hemosol Polymerized Discontinued Conjugated PHP Apex Bioscience PEG-human Hb Phase III PEG-Hb Enzon PEG-bovine Hb Discontinued MalPEG-Hb Sangart PEG-human Hb Phase III UC SF 52
53 Hemoglobin-based Oxygen Carriers Characteristic HemoPure PolyHeme MP4 RBC Volume (ml) Hb concentration (g/dl) P 50 (mmhg) Oncotic pressure (mmhg) Viscosity (cp) (WB) Methemoglobin (%) <15 <8 <10 <1 Half-life 19 hours 24 hours 24 hours 30 days Shelf life at 4 C 3 years 1.5 years >1 year 42 days Refrigeration No No No Yes UC SF 53
54 Hemoglobin-based Oxygen Carriers Still requires Hb Vasoactivity Gastrointestinal side effects Interference with laboratory results UC SF 54
55 Perfluorocarbon Emulsion UC SF 56
56 Oxygent : Perfluorocarbon Emulsion Lecithin stabilization Cleared very quickly by reticuloendothelial system (<6H) and exhaled unchanged Perflubron (perfluoroocytl bromide) UC SF 57
57 Perfluorocarbon Emulsion O2 Content (ml/100ml) PFC 2.4 g/dl PFC 1.6 g/dl Plasma Dissolved O 2 PaO2 (mmhg) UC SF 58
58 Perfluorocarbon Emulsion Requires high FIO2 to achieve higher oxygen content Increase in plasma cytokines (flu-like symptoms) Short half-life Long shelf life Easy to manufacture UC SF 59
59 AOC: How they compare Standl Infus Ther Transfus Med 2000;27: UC SF 60
60 Summary Few alternatives available to PRBC transfusion to increase arterial oxygen content The use of erythropoietin is not clear for most situations of anemia of critical illness UC SF 61
61 Summary Hemoglobin-based oxygen carriers are still in testing and development, along with perfluorocarbons There are even still other ideas UC SF 62
Alternatives to RBC Transfusion:
Alternatives to RBC Transfusion: beyond Erythropoietin and David Shimabukuro, MDCM Department of Anesthesia and Perioperative Care Medical Director, 13 ICU UC SF 1 Agenda Background Erythropoietin Hemoglobin-based
More informationBlood Substitutes. Roy Wang Ellen Quach November 2005
Blood Substitutes Roy Wang Ellen Quach November 2005 Why Do We Need Blood Substitutes? Provides disease-free alternative to transfusions Universal Compatibility Longer shelf-life than allogeneic blood
More informationP. ZACHEE MD PhD ALGEMEEN ZIEKENHUIS STUIVENBERG UNIVERSITAIRE ZIEKENHUIZEN LEUVEN HEM/91000P
P. ZACHEE MD PhD UNIVERSITAIRE ZIEKENHUIZEN LEUVEN ALGEMEEN ZIEKENHUIS STUIVENBERG HEM/91000P William Harvey (1578-1657) Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus "... Door een bloedvat
More informationCAROLINE THYES, ROMAN KOCIAN AND DONAT R. SPAHN Department of Anesthesiology University Hospital Lausanne Lausanne, Switzerland
CURRENT STATUS OF ARTIFICIAL O2 CARRIERS EUROANESTHESIA 2005 Vienna, Austria 28-31 May 2005 9RC4 CAROLINE THYES, ROMAN KOCIAN AND DONAT R. SPAHN Department of Anesthesiology University Hospital Lausanne
More informationDr. Puntarica Suwanprathes. Version 2007
Dr. Puntarica Suwanprathes Version 2007 O 2 and CO 2 transport in blood Oxyhemoglobin dissociation curve O 2 consumption (VO 2 ) CO 2 production (VCO 2 ) O 2 capacity O 2 content: CaO 2 or CvO 2 %saturation
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationWhy Old Blood is Bad. tales from the electronic perfusion record. Molly Marko, BS, BSE, CCP Geisinger Health System Danville, Pennsylvania
Why Old Blood is Bad tales from the electronic perfusion record Molly Marko, BS, BSE, CCP Geisinger Health System Danville, Pennsylvania Disclosure I have no financial relationship with any of the companies
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationDO 2 > VO 2. The amount of oxygen delivered is a product of cardiac output (L/min) and the amount of oxygen in the arterial blood (ml/dl).
Shock (Part 1): Review and Diagnostic Approach Jeffrey M. Todd, DVM, DACVECC University of Minnesota, St. Paul, MN Overview Shock is the clinical presentation of inadequate oxygen utilization, typically
More informationCritical Care Monitoring. Assessing the Adequacy of Tissue Oxygenation. Tissue Oxygenation - Step 1. Tissue Oxygenation
Critical Care Monitoring 1 Assessing the Adequacy of Tissue oxygenation is the end-product of many complex steps 2 - Step 1 Oxygen must be made available to alveoli 3 1 - Step 2 Oxygen must cross the alveolarcapillary
More informationGoal-directed vs Flow-guidedresponsive
Goal-directed vs Flow-guidedresponsive therapy S Magder Department of Critical Care, McGill University Health Centre Flow-directed vs goal directed strategy for management of hemodynamics S Magder Curr
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationGoal Directed Therapy : Liberal vs Restrictive Transfusion.. Syafri Kamsul Arif
Goal Directed Therapy : Liberal vs Restrictive Transfusion. Syafri Kamsul Arif Sepsis Perioperative EGDT PGDT PGDT Protocol Stroke volume optimization with fluid protocol SVV or PPV based GDT Protocol
More informationERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE
ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE WEIQIANG GAO HEM/ONC FELLOW FACULTY DISCUSSANT SIOBAN KEEL, MD OCT. 24, 2014 CASE PRESENTATION 25 F, a Jehovah s witness, w/ h/o synovial sarcoma
More informationHow to maintain optimal perfusion during Cardiopulmonary By-pass. Herdono Poernomo, MD
How to maintain optimal perfusion during Cardiopulmonary By-pass Herdono Poernomo, MD Cardiopulmonary By-pass Target Physiologic condition as a healthy person Everything is in Normal Limit How to maintain
More informationMechanical Ventilation. Assessing the Adequacy of Tissue Oxygenation. Tissue Oxygenation - Step 1. Tissue Oxygenation
1 Mechanical Ventilation Assessing the Adequacy of 2 Tissue oxygenation is the end-product of many complex steps - Step 1 3 Oxygen must be made available to alveoli 1 - Step 2 4 Oxygen must cross the alveolarcapillary
More informationFluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE
Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE In critically ill patients: too little fluid Low preload,
More informationBlood transfusions in sepsis, the elderly and patients with TBI
Blood transfusions in sepsis, the elderly and patients with TBI Shabbir Alekar MICU, CH Baragwanath Academic Hospital & The University of the Witwatersrand CCSSA Congress 11 June 2015 Packed RBC - complications
More informationTransfusions in Acute Care Too Little?
Transfusions in Acute Care Too Little? Keyvan Karkouti MD FRCPC MSc Associate Professor Department of Anesthesia; Department of Health Policy, Management, and Evaluation; University of Toronto Scientist
More information3. Which of the following would be inconsistent with respiratory alkalosis? A. ph = 7.57 B. PaCO = 30 mm Hg C. ph = 7.63 D.
Pilbeam: Mechanical Ventilation, 4 th Edition Test Bank Chapter 1: Oxygenation and Acid-Base Evaluation MULTIPLE CHOICE 1. The diffusion of carbon dioxide across the alveolar capillary membrane is. A.
More informationAnemia Management: Using Epo and Iron
Anemia Management: Using Epo and Iron Ky Stoltzfus, MD University of Kansas Medical Center Assistant Professor Department of Internal Medicine January 23, 2013 Regulation of red cell production Treatment
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationAdvances in Transfusion and Blood Conservation
Advances in Transfusion and Blood Conservation Arman Kilic, MD Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD No relevant financial relationships to disclose.
More informationNew Strategies in the Management of Patients with Severe Sepsis
New Strategies in the Management of Patients with Severe Sepsis Michael Zgoda, MD, MBA President, Medical Staff Medical Director, ICU CMC-University, Charlotte, NC Factors of increases in the dx. of severe
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationUTILITY of ScvO 2 and LACTATE
UTILITY of ScvO 2 and LACTATE Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland THIS TRIP SPONSORED AND PAID FOR BY STRUCTURE Physiology -
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationRed blood cell transfusions Risks, benefits, and surprises
SIOP PODC Supportive Care Education Presentation Date: 19 th January 2016 www.cure4kids.org Red blood cell transfusions Risks, benefits, and surprises Scott Howard, MD, MSc Professor, Universidad de Memphis,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationPresented by: Indah Dwi Pratiwi
Presented by: Indah Dwi Pratiwi Normal Fluid Requirements Resuscitation Fluids Goals of Resuscitation Maintain normal body temperature In most cases, elevate the feet and legs above the level of the heart
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationEVIDENCE BASED RED CELL TRANSFUSION. Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System
EVIDENCE BASED RED CELL TRANSFUSION Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System HISTORY Blood transfusion works (ie: red cell transfusion saves lives). based on
More informationEvidence-Based. Management of Severe Sepsis. What is the BP Target?
Evidence-Based Management of Severe Sepsis Michael A. Gropper, MD, PhD Professor and Vice Chair of Anesthesia Director, Critical Care Medicine Chair, Quality Improvment University of California San Francisco
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationFUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART
FUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART CINDY BITHER, MSN, ANP, ANP, AACC, CHFN CHIEF NP, ADV HF PROGRAM MEDSTAR WASHINGTON HOSPITAL CENTER CONFLICTS OF INTEREST NONE
More informationControversies in Transfusion Medicine
Controversies in Transfusion Medicine Jeffrey L. Carson, M.D. Richard C. Reynolds Professor of Medicine Chief, Division of General Internal Medicine Robert Wood Johnson Medical School New Brunswick, New
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationModule G: Oxygen Transport. Oxygen Transport. Dissolved Oxygen. Combined Oxygen. Topics to Cover
Topics to Cover Module G: Oxygen Transport Oxygen Transport Oxygen Dissociation Curve Oxygen Transport Studies Tissue Hypoxia Cyanosis Polycythemia Oxygen Transport Oxygen is carried from the lungs to
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAdvanced Monitoring of Cardiovascular and Respiratory Systems in Infants Kuwait 2018 Dr. Yasser Elsayed, MD, PhD Director of the Targeted Neonatal
Advanced Monitoring of Cardiovascular and Respiratory Systems in Infants Kuwait 2018 Dr. Yasser Elsayed, MD, PhD Director of the Targeted Neonatal Echocardiography, Point of Care and Hemodynamics Program
More informationDefining Optimal Perfusion during CPB. Carlo Alberto Tassi Marketing Manager Eurosets Italy
Defining Optimal Perfusion during CPB Carlo Alberto Tassi Marketing Manager Eurosets Italy It is a device able to monitor in a real time vital parameters and able to provide information regarding the transport
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationConventional vs. Goal Directed Perfusion (GDP) Management: Decision Making & Challenges
Conventional vs. Goal Directed Perfusion (GDP) Management: Decision Making & Challenges GEORGE JUSTISON CCP MANAGER PERFUSION SERVICES UNIVERSITY OF COLORADO HOSPITAL How do you define adequate perfusion?
More informationWhat is. InSpectra StO 2?
What is InSpectra StO 2? www.htibiomeasurement.com What is InSpectra StO 2? Hemoglobin O 2 saturation is measured in three areas: 1) Arterial (SaO 2, SpO 2 ) Assesses how well oxygen is loading onto hemoglobin
More informationUPMC Critical Care
UPMC Critical Care www.ccm.pitt.edu Shock and Monitoring Samuel A. Tisherman, MD, FACS, FCCM Professor Departments of CCM and Surgery University of Pittsburgh Shock Anaerobic metabolism Lactic acidosis
More informationAre Patients Hypoperfused in the ED? Rapid Perfusion Assessment in the Emergency Department
Are Patients Hypoperfused in the ED? Rapid Perfusion Assessment in the Emergency Department R. Benjamin Saldaña DO, FACEP Associate Medical Director Methodist Emergency Care Center, Houston TX Disclosure
More informationEmpowering the RT with New Noninvasive Monitoring Capabilities
Empowering the RT with New Noninvasive Monitoring Capabilities Thomas Lamphere BS, RRT, RPFT Executive Director, Pennsylvania Society for Respiratory Care Adjunct Instructor, Respiratory Care Program,
More informationHeinz-Hermann Weitkemper, EBCP. 4th Joint Scandinavian Conference in Cardiothoracic Surgery 2012 Vilnius / Lithuania
Heinz-Hermann Weitkemper, EBCP Everyone who earnestly practices perfusion is acting with the full belief that what they are doing is in the best interest of their patients. Perfusion can never be normal,
More informationMorris A. Blajchman, MD, FRCP(C) Emeritus Professor, McMaster University Hamilton, Ontario, CANADA
Morris A. Blajchman, MD, FRCP(C) Emeritus Professor, McMaster University Hamilton, Ontario, CANADA RBC TRANSFUSIONS: GENERAL PRINCIPLES RBCs are usually dispensed on a first-in, first-out basis. Storage
More informationFailure of the circulation to maintain Tissue cellular. Tissue hypoperfusion Cellular hypoxia SHOCK. Perfusion
Shock SHOCK Failure of the circulation to maintain Tissue cellular Perfusion Organs Syndrome RR
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationEarly Goal-Directed Therapy
Early Goal-Directed Therapy Where do we stand? Jean-Daniel Chiche, MD PhD MICU & Dept of Host-Pathogen Interaction Hôpital Cochin & Institut Cochin, Paris-F Resuscitation targets in septic shock 1 The
More informationUNIVERSA MEDICINA. Management of anemia among patients in intensive care units
UNIVERSA MEDICINA April-June 2008 Vol.27 - No.2 Management of anemia among patients in intensive care units Eveline Margo ABSTRACT Department of Physiology, Medical Faculty, Trisakti University Correspondence
More information3. Does the patient meet ALL of the following requirements? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Procrit - Retacrit (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., a Pfizer company, at , or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT (epoetin
More informationHow and why I give IV fluid Disclosures SCA Fluids and public health 4/1/15. Andrew Shaw MB FRCA FCCM FFICM
How and why I give IV fluid Andrew Shaw MB FRCA FCCM FFICM Professor and Chief Cardiothoracic Anesthesiology Vanderbilt University Medical Center 2015 Disclosures Consultant for Grifols manufacturer of
More informationREVIEW A REVIEW OF BLOOD SUBSTITUTES: EXAMINING THE HISTORY, CLINICAL TRIAL RESULTS, AND ETHICS OF HEMOGLOBIN-BASED OXYGEN CARRIERS
REVIEW A REVIEW OF BLOOD SUBSTITUTES: EXAMINING THE HISTORY, CLINICAL TRIAL RESULTS, AND ETHICS OF HEMOGLOBIN-BASED OXYGEN CARRIERS Jiin-Yu Chen, Michelle Scerbo, George Kramer doi: 10.1590/S1807-59322009000800016
More informationHemoglobin-based Oxygen Carriers
Anesthesiology 2009; 111:946 63 Copyright 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Hemoglobin-based Oxygen Carriers Current Status and Future Directions
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationDepartment of Intensive Care Medicine UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS
Department of Intensive Care Medicine UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS a mismatch between tissue perfusion and metabolic demands the heart, the vasculature
More informationGoal Directed Perfusion: theory, clinical results, and key rules
Goal Directed Perfusion: theory, clinical results, and key rules M. Ranucci Director of Clinical Research Dept of Cardiothoracic and Vascular Anesthesia and Intensive Care IRCCS Policlinico S.Donato Ranuuci,
More informationBlood Substitutes What They Are and How They Might Be Used
Pathology Patterns Reviews Blood Substitutes What They Are and How They Might Be Used Qun Dong, MD, PhD, 1 and Christopher P. Stowell, MD, PhD 1,2 Key Words: Blood substitute; Hemoglobin-based oxygen carrier;
More informationRecombinant human erythropoietin (epoetin alfa) has been used in clinical settings for
REVIEW ARTICLE Epoetin Alfa Clinical Evolution of a Pleiotropic Cytokine David H. Henry, MD; Peter Bowers, MD; Michael T. Romano, PhD; Robert Provenzano, MD Recombinant human erythropoietin (epoetin alfa)
More informationPatient Blood Management: Enough is Enough
Patient Blood Management: Enough is Enough Richard Benjamin, MBChB, PhD, FRCPath Professor of Pathology Georgetown University Medical Center Washington, D.C. Chief Medical Officer Cerus Corporation Concord,
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationTransfusion Limbo How Low Will You Go? Safely. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine
Transfusion Limbo How Low Will You Go? Safely Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine Objectives Benefits and risks of RBC administration in pediatric
More informationการอบรมว ทยาศาสตร พ นฐานทางศ ลยศาสตร เร อง นพ.ส ณฐ ต โมราก ล ภาคว ชาว ส ญญ ว ทยา คณะแพทยศาสตร โรงพยาบาลรามาธ บด มหาวทยาลยมหดล
การอบรมว ทยาศาสตร พ นฐานทางศ ลยศาสตร เร อง นพ.ส ณฐ ต โมราก ล ภาคว ชาว ส ญญ ว ทยา คณะแพทยศาสตร โรงพยาบาลรามาธ บด มหาวทยาลยมหดล Distributive shock Severe sepsis and Septic shock Anaphylactic shock Neurogenic
More informationThe Hemodynamic Puzzle
The Hemodynamic Puzzle SVV NIRS O 2 ER Lactate Energy Metabolism (Oxygen Consumption) (Ml/min/m 2 ) Oxygen Debt: To Pay or Not to Pay? Full Recovery Possible Delayed Repayment of O 2 Debt Oxygen Deficit
More informationClinical Controversies in Perioperative Medicine
Update on Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Medications & Perioperative
More informationTransfusion for the sickest ICU patients: Are there unanswered questions?
Transfusion for the sickest ICU patients: Are there unanswered questions? Tim Walsh Professor of Critical Care Edinburgh University None Conflict of Interest Guidelines on the management of anaemia and
More informationScience Evidence Cost
Anemia, Evidence, and Anemic Evidence: Is there a rational approach to perioperative transfusion? Elizabeth L Whitlock, MD, MSc Resident physician, Anesthesia & Perioperative Care University of California,
More informationMEDICATION GUIDE. Epogen (Ee-po-jen) (epoetin alfa)
MEDICATION GUIDE Epogen (Ee-po-jen) (epoetin alfa) Read this Medication Guide before you start Epogen, each time you refill your prescription, and if you are told by your healthcare provider that there
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationBlood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal
Blood transfusions in ICU: double-edged sword Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal Canadian Critical Care Trials Group Collaborating for Impact Leading
More informationNothing to disclose 9/25/2017
Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Nothing to disclose 1 Explain
More informationPROCRIT (epoetin alfa) for Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT (epoetin alfa)
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationDr Marina Karakantza Consultant Haematologist, NHSBT
Dr Marina Karakantza Consultant Haematologist, NHSBT Overview Definition of transfusion thresholds Mechanisms of adaptation to anaemia How RBC transfusion affect adaptation mechanisms to anaemia Triggers
More information9/25/2017. Nothing to disclose
Nothing to disclose Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Explain
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationSHOCK. Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital
SHOCK Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital 1 Definition Shock is an acute, complex state of circulatory dysfunction
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationA Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions
A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions Authors: Lesley J.J. Soril 1,2, MSc; Laura E. Leggett 1,2, MSc; Joseph Ahn, MSc
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDiagnosis and Management of Sepsis. Disclosures
Diagnosis and Management of Sepsis David Shimabukuro, MDCM Medical Director, 13 ICU Physician Lead, UCSF Sepsis Bundle Compliance and Mortality Reduction I have no disclosures Disclosures 1 The following
More informationBlood and blood component therapy in the critically ill patient
Blood and blood component therapy in the critically ill patient Dr Liesel Bösenberg Specialist Physician and Fellow in Critical Care Kalafong Hospital Points that we shall ponder Transfusion triggers EGDT
More informationLiberale versus restriktive EK-Transfusion
SWISSTRANSFUSION 2016 Thursday, August 25, 2016; 11:00 11:30 am Liberale versus restriktive EK-Transfusion Reto Schüpbach Dokumentenname Datum Seite 0 Pull out, you hit the artery! www.pinterest.com Dokumentenname
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More information